SCM
GALT icon

Stevens Capital Management’s Galectin Therapeutics GALT Stock Holding History

Stevens Capital Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-13,288
Closed -$184K – 1083
2014
Q2 		$184K Buy
+13,288
New +$165K ﹤0.01% 940

Other funds holding GALT

CCA
Catalyst Capital Advisors Huntington, New York $5.37B AUM 18.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Stevens Capital Management's GALT Position: Q3 2014 in Review

Stevens Capital Management sold out of Galectin Therapeutics (GALT) in Q3 2014, closing a stake of 13,288 shares — an estimated $184K sold.

Stevens Capital Management first reported a position in GALT in Q2 2014 and held it in 1 quarter. The position peaked at $184K in Q2 2014. 63 funds tracked by Wall St. Rank hold GALT as of Q3 2014.

  • Stevens Capital Management reported no remaining Galectin Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Stevens Capital Management sold 13,288 Galectin Therapeutics shares in Q3 2014, an estimated $184K.
  • Stevens Capital Management first reported a position in Galectin Therapeutics in Q2 2014 and held it in 1 quarter.
  • Stevens Capital Management's Galectin Therapeutics position peaked at $184K in Q2 2014.
  • 63 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2014.

Based on Stevens Capital Management's 13F filing for Q3 2014, filed 7 Nov 2014.